Wall Street brokerages forecast that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will post earnings per share (EPS) of ($0.06) for the current quarter, Zacks reports. Zero analysts have provided estimates for Catalyst Pharmaceuticals’ earnings, with estimates ranging from ($0.07) to ($0.05). Catalyst Pharmaceuticals also reported earnings per share of ($0.06) during the same quarter last year. The firm is scheduled to report its next quarterly earnings results on Wednesday, May 9th.
According to Zacks, analysts expect that Catalyst Pharmaceuticals will report full year earnings of ($0.36) per share for the current financial year, with EPS estimates ranging from ($0.58) to ($0.23). For the next financial year, analysts forecast that the company will report earnings of ($0.11) per share, with EPS estimates ranging from ($0.23) to ($0.01). Zacks’ EPS averages are an average based on a survey of research analysts that cover Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.06) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.06).
Several hedge funds and other institutional investors have recently made changes to their positions in CPRX. Consonance Capital Management LP grew its stake in shares of Catalyst Pharmaceuticals by 1,111.4% during the 4th quarter. Consonance Capital Management LP now owns 4,473,607 shares of the biopharmaceutical company’s stock valued at $17,492,000 after buying an additional 4,104,309 shares during the period. Millennium Management LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $8,082,000. Emerald Advisers Inc. PA purchased a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $5,364,000. Driehaus Capital Management LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $4,812,000. Finally, EAM Investors LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $4,076,000. 54.70% of the stock is owned by institutional investors.
Catalyst Pharmaceuticals stock traded down $0.22 during mid-day trading on Monday, reaching $2.56. 836,176 shares of the company’s stock traded hands, compared to its average volume of 815,829. The stock has a market cap of $285.11, a PE ratio of -11.64 and a beta of 1.41. Catalyst Pharmaceuticals has a 12-month low of $1.62 and a 12-month high of $4.51.
COPYRIGHT VIOLATION NOTICE: “Catalyst Pharmaceuticals Inc (CPRX) Expected to Post Earnings of -$0.06 Per Share” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3297487/catalyst-pharmaceuticals-inc-cprx-expected-to-post-earnings-of-0-06-per-share.html.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.